Opyl makes a strategic board recruitment as it looks to commercialise its product offerings
Health & Biotech
Health & Biotech
Link copied to
The recruitment of Dr Megan Robertson to the Opyl’s board will give the company the depth and experience it needs to expand the business globally.
AI-based digital health company Opyl (ASX:OPL) has announced the appointment of Dr Megan Robertson to the Opyl board as a non-executive director, as the company looks to expand the commercialisation of its product offerings in the global clinical trial sector.
Dr Robertson’s extensive clinical trial experience will bring not only expertise in the health sector, but also her networks within the industry.
“We are extremely pleased to welcome Megan to the board. Megan brings an enormous amount of clinical and commercial experience and in- depth knowledge in the health sector which will contribute significantly to the company’s strategy,” commented Opyl chairman, Dr Julian Chick.
“Megan’s expertise and networks will complement the Opyl leadership team, particularly as we further commercialise our product offerings.”
Dr Robertson is an alumna of the University of Melbourne, where she completed a Bachelor of Medicine, Bachelor of Surgery (MBBS).
Her incumbent roles include group chief research officer at St Vincent’s Health Australia, and director of research at St Vincent’s Hospital, Melbourne.
She is also a senior intensive care consultant at Epworth HealthCare in Richmond and Freemasons.
Dr Robertson currently sits on several boards, which include the boards of the Digital Health CRC, St Vincent’s Institute of Medical Research, FearLess (PTSD-ANZ), Queen’s College (University of Melbourne), and the Tuckwell Scholarship Selection Panel at ANU.
Her governmental experience is extensive, and includes working with national bodies such as Australian Commission on Safety and Quality in Healthcare, AusBiotech, and the National Health and Medical Research Council.
Her previous experiences include senior positions held as the director of Professional Affairs at CICM, the executive director of Research at Epworth HealthCare, and as the co-director of the Intensive Care Unit at Epworth Freemasons.
Dr Robertson has successfully led major initiatives in the St Vincent’s Research Directorate, including establishing the St Vincent’s Research Valet Service, and developing the Victorian Clinical Trial Gateway portal.
She has facilitated research activities of the Research Governance Unit, and built linkages between clinicians/researchers and the industry, as well as linkages between clinicians/researchers and the community.
Dr Robertson is also a fellow of the Royal Australian College of Physicians (FRACP), the Australian and New Zealand College of Anaesthetists (FANZCA), and the College of Intensive Care Medicine (FCICM).
With her extensive experience and credentials in the clinical research and healthcare sector, Dr Robertson believes that she can make a significant contribution to Opyl’s expansion globally.
“Opyl has set a tremendous foundation for its technology platforms and with my clinical expertise and experience, I see the capability and global opportunity for the company,” she said.
“It is with great excitement and enthusiasm that I join the Opyl board to assist in making a significant contribution to the ongoing growth of the business.”
Opyl works with biopharma, medtech and government organisations to provide clinical trial recruitment and retention solutions, by utilising deep social media insights.
Its share price has risen by more than 180 per cent within the last 12 months.
This article was developed in collaboration with Opyl, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.